Simultaneous determination of paroxetine, risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with coulometric detection.
A method for the simultaneous determination of paroxetine, risperidone and its main metabolite 9-hydroxyrisperidone in human plasma has been developed. The procedure involved a multistep solid-phase liquid extraction with an internal standard. The drugs were separated on a cyano column followed by coulometric detection. This method described here has sufficient sensitivity to quantitate paroxetine accurately in the range 5-500 ng/ml with a lower limit of detection of 1 ng/ml and risperidone and its main metabolite 9-hydroxyrisperidone in the range 2-100 ng/ml with a lower limit of detection of 1 ng/ml when 1 ml of plasma was used for the analysis. The precision, accuracy and specificity have been proven, and show that the method is reliable for clinical studies and routine drug monitoring.
Schatz
D S
DS
Division of Neurochemistry, Department of Psychiatry, University Hospital Innsbruck, Austria.
Saria
A
A
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D003124:Colorimetry; D016903:Drug Monitoring; D006801:Humans; D007555:Isoxazoles / Q000097:blood*; D000068882:Paliperidone Palmitate; D017374:Paroxetine / Q000097:blood*; D011743:Pyrimidines / Q000097:blood*; D018967:Risperidone / Q000097:blood*; D013056:Spectrophotometry, Ultraviolet
D007555:Isoxazoles; D011743:Pyrimidines; D017374:Paroxetine; D018967:Risperidone; D000068882:Paliperidone Palmitate